Document Detail


Passive active prophylaxis against Hepatitis B in children with acute lymphoblastic leukemia.
MedLine Citation:
PMID:  12363466     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The aim of this study was to assess the antibody response to combined passive active immunisation versus active immunisation along with interferon against Hepatitis B in 60 patients with acute lymphoblastic leukemia (ALL) between 1 and 21 years of age with negative Hepatitis B virus (HBV) serology at presentation. Thirty-one patients received combined passive active immunisation with human specific Hepatitis B immunoglobulin (HEPABIG-VHB Pharmaceuticals) and Hepatitis B vaccine (arm I) and 29 patients received active immunisation along with interferon (arm II). Protective antibody levels were detected in 89.6 and 21% patients, respectively, at the 6-month evaluation. Infection with HBV occurred in 17 and 59% patients, respectively, at the 6-month evaluation. Interferon, thus, failed to serve the role as a vaccine adjuvant. At the 9-month evaluation of patients who received immunoglobulin, protective antibody titers were lost in 8 out of 19 evaluable patients (42%) and of these, 3 patients became HBsAg reactive at this point of time. This study indicated that 47.3% patients undergoing aggressive chemotherapy responded to combined passive active prophylaxis with protective titers of antiHBs at the 9-month evaluation. However, the rate of HBV infection was greatly reduced to 27%. We suggest that usage of passive immunisation in the aggressive phase, followed by active immunisation after cessation of intense chemotherapy would be a better option to increase the rates of protective antibody levels in these immunocompromised patients with leukemia.
Authors:
Saika Somjee; Suresh Pai; Purvish Parikh; Shripad Banavali; Rohini Kelkar; Suresh Advani
Related Documents :
9314136 - Hepatitis b associated liver failure following bone marrow transplantation.
17596666 - Rantes, mcp-1, ccr2, ccr5, cxcr1 and cxcr4 gene polymorphisms are not associated with t...
2963986 - Review of hepatitis non-a, non-b: the potential hazards in dental care.
20472596 - Long-term safety of anti-tnf treatment in patients with rheumatic diseases and chronic ...
11261756 - Th1/th2 shift in hiv lymph nodes: no contribution of cd6o cells.
20299496 - Impact of 48 week lopinavir/ritonavir monotherapy on blood cell-associated hiv-1-dna in...
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Leukemia research     Volume:  26     ISSN:  0145-2126     ISO Abbreviation:  Leuk. Res.     Publication Date:  2002 Nov 
Date Detail:
Created Date:  2002-10-04     Completed Date:  2002-12-09     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  7706787     Medline TA:  Leuk Res     Country:  England    
Other Details:
Languages:  eng     Pagination:  989-92     Citation Subset:  IM    
Affiliation:
Department of Medical Oncology, Tata Memorial Hospital, Dr. Ernest Borges Road, Parel, Mumbai 400012, India.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acute Disease
Adolescent
Adult
Child
Child, Preschool
Combined Modality Therapy
Hepatitis B / complications,  prevention & control*
Hepatitis B Antibodies / blood
Hepatitis B Surface Antigens / analysis
Hepatitis B Vaccines / therapeutic use*
Humans
Immunization, Passive*
Infant
Interferon Alfa-2b / therapeutic use
Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications*
Vaccination*
Vaccines, DNA / therapeutic use*
Chemical
Reg. No./Substance:
0/Hepatitis B Antibodies; 0/Hepatitis B Surface Antigens; 0/Hepatitis B Vaccines; 0/Vaccines, DNA; 99210-65-8/Interferon Alfa-2b

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Analysis of CHK2 in patients with myelodysplastic syndromes.
Next Document:  Comparison of cytogenetics with FISH in 40 myelodysplastic syndrome patients.